About Ducentis BioTheapeutics
Ducentis BioTheapeutics is a Healthcare company based in Witney (United Kingdom) founded in 2015, and was acquired by Arcutis in September 2022. Preclinical therapeutics for inflammatory and auto-immune diseases are developed. Ducentis BioTheapeutics has raised $2.29 million across 5 funding rounds from investors including Arcutis, Oxford Technology and LifeArc. The company has 6 employees. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Diversified and Immunology. Its legal entity is DUCENTIS BIOTHERAPEUTICS LTD.
Company details
Founded in 2015, Ducentis BioTheapeutics operates as a UK-based preclinical biotech firm in Witney, focusing on therapeutics for inflammatory and auto-immune conditions. An existing protein is modified to enhance its immunoregulatory role, targeting the CD200CD200R pathway to suppress immune responses. A portfolio of CD200 molecules is advanced through collaborations with Prosarix, Syngene, GVK Bio, and KWS BioTest, supported by seed funding from Oxford Technology.
- Headquarters Witney, United Kingdom
- Employees 6
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website ducentisbio.com
- Acquired by Arcutis (Sep 2022)
- Legal Name Ducentis Biotherapeutics Ltd.
- Date of Incorporation 12 Nov, 2014
- Jurisdiction 10 TEMPLE BACK, BRISTOL, UNITED KINGDOM
Funding Insights of Ducentis BioTheapeutics
Ducentis BioTheapeutics has successfully raised a total of $2.29M across 5 strategic funding rounds. The most recent funding activity was a Seed round of $1.9 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.29M
- Total Rounds 5
- Last Round Seed — $1.9M
- First Round $77,538
(Jul 2015)
- Investors Count 2
All 5 funding rounds of Ducentis BioTheapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $1.9M | Seed | – | LifeArc | |
| Mar 2018 | $63,601 | Seed | – | – | |
| Mar 2017 | $199,108 | Seed | – | – | |
| Dec 2015 | $45,669 | Seed | – | – | |
| Jul 2015 | $77,538 | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Ducentis BioTheapeutics
Ducentis BioTheapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Arcutis, Oxford Technology and LifeArc.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage micro-VC investments are focused on UK companies. | 1983 | oxfordtechnology.com | ||
Medical research and treatments are supported by the community foundation. | 1992 | lifearc.org | London, United Kingdom | |
Immunotherapeutic solutions for dermatological conditions are developed. | 2016 | arcutis.com | Westlake Village, United States |
Investor details for Ducentis BioTheapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ducentis BioTheapeutics
4 dated milestones of Ducentis BioTheapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Ducentis BioTheapeutics is founded.
- Funding First funding round of $78K.
- Funding Latest funding round, Seed, of $1.9M.
- Exit Acquired by Arcutis.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ducentis Biotheapeutics
Complete news archive for Ducentis BioTheapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ducentis BioTheapeutics
Ducentis BioTheapeutics was founded in 2015.
Ducentis BioTheapeutics is headquartered in Witney, United Kingdom. It is registered at Witney, Oxfordshire, United Kingdom.
Ducentis BioTheapeutics is a funded company, having raised a total of $2.29M across 5 funding rounds to date. The company's 1st funding round was a Seed of $77.54K, raised on Jul 2015.
Ducentis BioTheapeutics has 6 employees.
Founded in 2015, Ducentis BioTheapeutics operates as a UK-based preclinical biotech firm in Witney, focusing on therapeutics for inflammatory and auto-immune conditions. An existing protein is modified to enhance its immunoregulatory role, targeting the CD200CD200R pathway to suppress immune responses. A portfolio of CD200 molecules is advanced through collaborations with Prosarix, Syngene, GVK Bio, and KWS BioTest, supported by seed funding from Oxford Technology.
Ducentis BioTheapeutics has 3 investors. Key investors include Arcutis, Oxford Technology, and LifeArc.
Ducentis BioTheapeutics operates through Ducentis Biotherapeutics Ltd..
Yes. Ducentis BioTheapeutics was acquired by Arcutis in September 2022.